DDR2 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, a squamous cell lung cancer patient with a DDR2 mutation and no EGFR mutation demonstrated partial response to dasatinib and erolotinib [42] while a second patient with co-occurring CML and squamous cell lung cancer, which possessed a DDR2 mutation, showed a complete metabolic response in the lung tumor after treatment with dasatinib [79].